[
  {
    "ts": null,
    "headline": "How Did Tempus AI Power Its Move to Positive EBITDA in Q3?",
    "summary": "TEM hits its first positive adjusted EBITDA as strong Genomics and Data Licensing growth pairs with tighter cost discipline.",
    "url": "https://finnhub.io/api/news?id=ff385de1554f6d55c0caded262e0a63c684b8c5616f8bf53a50f409ca5e875cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763387700,
      "headline": "How Did Tempus AI Power Its Move to Positive EBITDA in Q3?",
      "id": 137506802,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "TEM hits its first positive adjusted EBITDA as strong Genomics and Data Licensing growth pairs with tighter cost discipline.",
      "url": "https://finnhub.io/api/news?id=ff385de1554f6d55c0caded262e0a63c684b8c5616f8bf53a50f409ca5e875cc"
    }
  },
  {
    "ts": null,
    "headline": "How the Narrative Around Quest Diagnostics Is Evolving After Recent Results and Analyst Updates",
    "summary": "Quest Diagnostics' fair value estimate remains steady at $197.25 per share, with only a slight uptick in the discount rate. This reflects minimal change in the firm's valuation assessment. While the company continues to project steady revenue growth, recent analyst sentiment highlights both enthusiasm and caution following strong quarterly results and an impressive guidance update. Stay tuned to discover how evolving analyst views and company performance can help you navigate future updates...",
    "url": "https://finnhub.io/api/news?id=b6b8d8648362df74bfb115dd0cdcfd0b54ce1339cc653e2725872542d84f162e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763338467,
      "headline": "How the Narrative Around Quest Diagnostics Is Evolving After Recent Results and Analyst Updates",
      "id": 137502144,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics' fair value estimate remains steady at $197.25 per share, with only a slight uptick in the discount rate. This reflects minimal change in the firm's valuation assessment. While the company continues to project steady revenue growth, recent analyst sentiment highlights both enthusiasm and caution following strong quarterly results and an impressive guidance update. Stay tuned to discover how evolving analyst views and company performance can help you navigate future updates...",
      "url": "https://finnhub.io/api/news?id=b6b8d8648362df74bfb115dd0cdcfd0b54ce1339cc653e2725872542d84f162e"
    }
  }
]